Warfarin Monitoring with International Normalized Ratio

Introduction to Warfarin and INR

The American College of Cardiology states that warfarin is the anticoagulant monitored by International Normalized Ratio (INR), which was specifically developed and validated to standardize prothrombin time (PT) measurements for patients receiving vitamin K antagonist (VKA) therapy 1, 2.

Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, and X), causing prolongation of the PT that must be carefully monitored to balance thrombosis prevention against bleeding risk 1.
The INR standardizes PT measurements across different thromboplastin reagents and laboratories, calculated as INR = (patient PT/mean normal PT)^ISI, where ISI is the International Sensitivity Index of the thromboplastin used 1.
INR was specifically designed and validated using plasma samples from patients on stable VKA therapy, making it the gold standard for warfarin monitoring 2, 3.

Most indications require INR 2.0-3.0, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism 4.
Higher intensity INR 2.5-3.5 is recommended for mechanical heart valves and certain high-risk post-MI patients 4.
INR values below 2.0 increase thromboembolism risk, while values above the therapeutic range sharply increase bleeding risk 4.

Unfractionated heparin (UFH) is monitored by activated partial thromboplastin time (aPTT), not INR 1.
Rivaroxaban is a direct factor Xa inhibitor that does not require routine coagulation monitoring and does not affect INR in a predictable, dose-dependent manner suitable for therapeutic monitoring 2.

The INR is only valid for warfarin monitoring—it should not be used to assess bleeding risk or guide plasma transfusion in patients not taking VKAs, as it was never designed or validated for these purposes 2, 5.